{"entity":{"type":"insider","cik":"0002019493","url":"/insider/0002019493","json_url":"/insider/0002019493.json","name":"Dube Michael P","name_source":"as-filed","also_issuer":false,"cross_url":null},"coverage_statement":{"n_transactions":6,"n_filings":6,"first":"2024-10-04","last":"2026-07-06","span_basis":"filed_date"},"name_variants":[{"name":"Dube Michael P","source":"filing","n_filings":6,"first_seen":"2024-10-04","last_seen":"2026-07-06"}],"transactions":[{"id":5925403,"accession":"0002019493-26-000002","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0002019493-26-000002","line_url":"/filing/0002019493-26-000002#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0002019493","owner_name":"Dube Michael P","owner_display_name":"Dube Michael P","owner_url":"/insider/0002019493","role":"Officer (VP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2641.0,"shares_display":"2,641","price_per_share":16.78,"price_display":"16.78","price_state":"stated","total_value":44315.98,"total_display":"44,315.98","total_whole":"44,316","shares_owned_after":66886.0,"shares_owned_after_display":"66,886","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-07-01","filed_date":"2026-07-06","scope":"insider"},{"id":5781998,"accession":"0001193125-26-006264","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-26-006264","line_url":"/filing/0001193125-26-006264#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0002019493","owner_name":"Dube Michael P","owner_display_name":"Dube Michael P","owner_url":"/insider/0002019493","role":"Officer (VP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2989.0,"shares_display":"2,989","price_per_share":9.21,"price_display":"9.21","price_state":"stated","total_value":27528.69,"total_display":"27,528.69","total_whole":"27,529","shares_owned_after":52277.0,"shares_owned_after_display":"52,277","ownership_form":"D","is_10b5_1":null,"transaction_date":"2026-01-05","filed_date":"2026-01-07","scope":"insider"},{"id":5069391,"accession":"0001193125-25-230420","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0001193125-25-230420","line_url":"/filing/0001193125-25-230420#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0002019493","owner_name":"Dube Michael P","owner_display_name":"Dube Michael P","owner_url":"/insider/0002019493","role":"Officer (VP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1871.0,"shares_display":"1,871","price_per_share":17.38,"price_display":"17.38","price_state":"stated","total_value":32517.98,"total_display":"32,517.98","total_whole":"32,518","shares_owned_after":55266.0,"shares_owned_after_display":"55,266","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-10-01","filed_date":"2025-10-03","scope":"insider"},{"id":4947320,"accession":"0000950170-25-093844","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-093844","line_url":"/filing/0000950170-25-093844#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0002019493","owner_name":"Dube Michael P","owner_display_name":"Dube Michael P","owner_url":"/insider/0002019493","role":"Officer (VP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2503.0,"shares_display":"2,503","price_per_share":9.95,"price_display":"9.95","price_state":"stated","total_value":24904.85,"total_display":"24,904.85","total_whole":"24,905","shares_owned_after":57137.0,"shares_owned_after_display":"57,137","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-07-02","filed_date":"2025-07-03","scope":"insider"},{"id":4339599,"accession":"0000950170-25-003032","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-25-003032","line_url":"/filing/0000950170-25-003032#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0002019493","owner_name":"Dube Michael P","owner_display_name":"Dube Michael P","owner_url":"/insider/0002019493","role":"Officer (VP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":1372.0,"shares_display":"1,372","price_per_share":12.18,"price_display":"12.18","price_state":"stated","total_value":16710.96,"total_display":"16,710.96","total_whole":"16,711","shares_owned_after":45640.0,"shares_owned_after_display":"45,640","ownership_form":"D","is_10b5_1":null,"transaction_date":"2025-01-03","filed_date":"2025-01-07","scope":"insider"},{"id":3256022,"accession":"0000950170-24-112980","txn_seq":1,"anchor":"line-1","filing_url":"/filing/0000950170-24-112980","line_url":"/filing/0000950170-24-112980#line-1","is_derivative":false,"issuer_cik":"0001652130","issuer_name":"Intellia Therapeutics, Inc.","issuer_ticker":"NTLA","issuer_name_source":null,"issuer_url":"/issuer/0001652130","owner_cik":"0002019493","owner_name":"Dube Michael P","owner_display_name":"Dube Michael P","owner_url":"/insider/0002019493","role":"Officer (VP, Chief Accounting Officer)","role_mark":"O","role_mark_label":"Officer (VP, Chief Accounting Officer)","role_mark_generic":"Officer","n_reporting_owners":null,"other_reporting_owners":null,"officer_title":"VP, Chief Accounting Officer","security_title":"Common Stock","transaction_code":"S","transaction_label":"Open-market sale","open_market":true,"acquired_disposed":"D","direction_word":"disposed","shares":2012.0,"shares_display":"2,012","price_per_share":19.01,"price_display":"19.01","price_state":"stated","total_value":38248.12,"total_display":"38,248.12","total_whole":"38,248","shares_owned_after":47012.0,"shares_owned_after_display":"47,012","ownership_form":"D","is_10b5_1":null,"transaction_date":"2024-10-02","filed_date":"2024-10-04","scope":"insider"}],"collapsed":true,"next_cursor":null,"ledger_fault":false,"count":{"value":6,"kind":"exact"},"open_market_only":false,"composition":{"kind":"exact","rows":[{"code":"P","label":"Open-market purchase","n":0,"open_market":true},{"code":"S","label":"Open-market sale","n":6,"open_market":true},{"code":"M","label":"Option exercise","n":0,"open_market":false},{"code":"A","label":"Grant or award","n":0,"open_market":false},{"code":"F","label":"Tax withholding","n":0,"open_market":false},{"code":"D","label":"Disposition to the issuer","n":0,"open_market":false},{"code":"X","label":"In-the-money option exercise","n":0,"open_market":false}],"total":6},"affiliations":[{"type":"issuer","type_label":"ISSUER","cik":"0001652130","name":"Intellia Therapeutics, Inc.","url":"/issuer/0001652130","role":"Officer (VP, Chief Accounting Officer)","n_filings":6,"first_seen":"2024-10-04","last_seen":"2026-07-06"}],"order_statement":"Newest transaction date first, id breaking the tie.","canonical_url":"https://ebomi.com/insider/0002019493","retrieved_at":"2026-08-24T15:03:44+00:00","coverage":{"filings":1506293,"transactions":4290787,"issuers":28597,"insiders":152303,"first_filed_date":"2003-06-30","last_filed_date":"2026-08-21","last_ingest":"2026-08-22T05:23:40.159918+00:00","counts_are":{"filings":"estimate","transactions":"estimate","issuers":"estimate","insiders":"estimate"},"source":"SEC EDGAR Form 4 filings, parsed by ebomi","fault":false},"license":{"underlying_records":"US SEC filings are public records of the United States government and are not subject to copyright. The transactional facts in them are not ours to license.","this_presentation":"The parsing, normalisation, curation, and presentation are ebomi's own work.","grant":"undecided","grant_note":"The open licence for ebomi's own layer is an open owner decision (SPEC-20260731T1159Z open question 3: CC BY 4.0 or CC0 with a citation request). Until it is taken, no grant is asserted here.","citation_request":"Balogh, A. Insider trading. Scientific Data 10, 237 (2023)","url":"https://ebomi.com/license"},"fair_use":{"policy":"These JSON endpoints are open and unauthenticated. Please read them at a human pace, identify your client in the User-Agent header, and use the published dataset for bulk work rather than crawling page by page.","bulk_alternative":"doi:10.1038/s41597-023-02147-6"}}